Investigational Drug Details
| Drug ID: | D364 |
| Drug Name: | Testosterone Undecanoate |
| Synonyms: | Testosterone undecanoate; Testosterone undeconate; Testosterone undecylate |
| Type: | Chemical drug |
| DrugBank ID: | DB13946 |
| DrugBank Description: | Testosterone undecanoate is the ester prodrug of testosterone and has a midchain fatty acid at the 17Beta position. It is available as an intramuscular injection and as an oral capsule, and is indicated for treatment of testosterone deficiency. It should be noted that testosterone undecanoate is only indicated for treatment of hypogonadal conditions with structural or genetic etiologies and should not be used to manage "age-related hypogonadism". |
| PubChem ID: | 65157 |
| CasNo: | 5949-44-0 |
| Repositioning for NAFLD: | Yes |
| SMILES: | C[C@@]12[C@@H]3[C@H]([C@H]4[C@@](CC3)(C)[C@H](CC4)OC(=O)CCCCCCCCCC)CCC1=CC(=O)CC2 |
| Structure: |
|
| InChiKey: | UDSFVOAUHKGBEK-CNQKSJKFSA-N |
| Molecular Weight: | 456.711 |
| DrugBank Targets: | Androgen receptor agonist; Estrogen receptor alpha; Mineralocorticoid receptor |
| DrugBank MoA: | Testosterone is produced by Leydig cells and exerts it's effects by binding to androgen receptors throughout the body. Testosterone affects the voice, genitalia, mood, and influences muscle growth and protein expression. Accordingly, males with low levels of testosterone often experience decreased libido, fatigue, mood changes and dysphoria. Exogenous sources of testosterone are designed to mimic the effects of endogenous testosterone. |
| DrugBank Pharmacology: | Testosterone plays a key role in male sexual differentiation and is involved in regulation of hematopoiesis, body composition, and bone metabolism. As a result, testosterone replacement therapy in males with hypogonadism can result in improved sexual function, increased lean body mass, bone density, erythropoiesis, prostate size, and changes in lipid profiles. |
| DrugBank Indication: | Testosterone undecanoate is indicated for replacement therapy in adult males with conditions that are linked with an absence or deficiency in endogenous testosterone production. |
| Targets: | AR agonist |
| Therapeutic Category: | Hormone replacement drug |
| Clinical Trial Progress: | Phase 3 on-going (ACTRN12619000701123) |
| Latest Progress: | Under clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0206 | NCT01919294 | Phase 2 | Completed | No Results Available | July 2013 | April 26, 2017 | Details |
| L0531 | EUCTR2012-002564-27-GB | Phase 2 | Not Recruiting | No Results Available | 04/01/2013 | 30 April 2019 | Details |
| L0747 | ACTRN12619000701123 | Phase 3 | Not Recruiting | No Results Available | 09/05/2019 | 15 July 2019 | Details |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A01959 | 34552789 | Arab J Urol | Testosterone treatment improves liver function and reduces cardiovascular risk: A long-term prospective study. | Details |
| A04952 | 33439074 | Aging Male | Long-term testosterone therapy improves liver parameters and steatosis in hypogonadal men: a prospective controlled registry study. | Details |
| A49756 | 35646271 | World J Hepatol | Testosterone therapy reduces hepatic steatosis in men with type 2 diabetes and low serum testosterone concentrations. | Details |
| A52045 | 31925559 | Metabolomics | Anabolic androgenic steroids exert a selective remodeling of the plasma lipidome that mirrors the decrease of the de novo lipogenesis in the liver. | Details |